BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Global demand for the vaccine maker's COVID-19 drug remains strong.

Why BioNTech Stock Climbed Today

BioNTech SE (NASDAQ:BNTX ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Sylke Maas - VP, IR and Business Strategy Ugur Sahin - Co-Founder & CEO Ozlem Tureci - Co-Founder & Chief Medical Officer Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Cory Kasimov - JPMorgan Chase & Co. Christopher Zopf - Goldman Sachs Group Akash Tewari - Jefferies Zhiqiang Shu - Berenberg Daina Graybosch - SVB Leerink Operator Welcome to the BioNTech First Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas.

BioNTech SE (BNTX) CEO Ugur Sahin on Q1 2022 Results - Earnings Call Transcript

BNTX stock is climbing on Monday after BioNTech reported better-than-expected results. The company credits Covid-19 vaccine innovation.

BNTX Stock Treks Higher on BioNTech's Vaccine Sales

BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook. BioNTech reported first-quarter revenue of 6.37 billion euros ($6.72 billion), which was up from €2.05 billion year-over-year.

Why BioNTech Stock Is Rising Today

The shares of BioNTech SE  (NASDAQ:BNTX) are inching higher ahead of the open, last seen up 0.8% at $137.20, after the pharma giant reported better-than-expected first-quarter earnings, as well as a revenue beat.

BioNTech Stock Rises After Reiterating Guidance

BioNTech BNTX, -4.05% , the U.S-listed German biotech, said its first-quarter profit more than tripled to €3.7 billion ($3.9 billion), or €14.24 per share, from €1.13 billion, or €4.39 per share, as revenue jumped to €6.38 billion from €2.05 billion, mostly on its share of COVID-19 vaccine sales from Pfizer and Fosun Pharma as well as direct sales to customers in Germany and Turkey. Analysts polled by FactSet had expected earnings of €9.70 per share on sales of €4.59 billion.

BioNTech earnings jump after 750 million COVID vaccines invoiced

BioNTech said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer, but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales.

BioNTech posts tripled Q1 vaccine sales but still flags full-year decline

BioNTech earns €14.24 a share in the first quarter on revenue of €6.37 billion.

BioNTech Earnings and Sales Top Wall Street Forecasts

Conference call and webcast scheduled for May 9, 2022, at 8:00 am ET (2:00 pm CET)

BioNTech Announces First Quarter Financial Results and Corporate Update

Novavax

Palantir Technologies

Plug Power

Lordstown Motors

The first-quarter reporting season is well and truly underway. Data from Factset show that about  87% of S&P 500 companies have reported their quarterly results, with 79% reporting positive earnings per share, or EPS, surplus, and 74% ringing in revenue upside.

Palantir, Plug Power, Novavax, BioNTech, Lordstown: 5 Key Earnings To Watch Today

Disney

Occidental Petroleum

Rivian Automotive

First quarter earnings reports this week include BioNTech, Palantir, Simon Property Group, Tyson Foods, Electronic Arts, Occidental Petroleum, and Walt Disney. Plus, inflation data.

Disney, Occidental, Rivian, Palantir, BioNTech, and Other Stocks to Watch This Week

The company launches a two-year share buyback program.

Why BioNTech Stock Crushed the Market Today

Gilead Sciences

Eli Lilly

Merck

Check out these pharmaceutical stocks in the stock market today.

Top Pharmaceutical Stocks To Watch In May 2022

There's trouble ahead, but a few new solutions are on the way too.

Thinking of Buying BioNTech? Consider These 3 Things First

It's unlikely to be a one-hit wonder. And that should be great for patient investors.

3 Things About BioNTech That Smart Investors Know

Pfizer

BioNTech SE BNTX, -2.86% and Pfizer Inc. PFE, -0.42% said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5 years old sometime before the end of June. The announcement was included in a news release stating that the companies requested Food and Drug Administration authorization for a COVID-19 booster dose in children between the ages of 5 and 11 years old.

BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter

BioNTech SE BNTX, -2.24% and Pfizer Inc. PFE, -0.17% said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults.

BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children

Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.

BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022

The vaccine maker got a dose of good news late last week, and ongoing lockdowns in China perhaps spurred some optimism.

Why BioNTech SE Was Surging Today

Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China. Rising COVID-19 cases in China's capital Beijing and Shanghai, where enforcement of a strict "zero-COVID" policy is ongoing, have drawn.

What's Happening With BioNTech SE Shares?

It could be an important sign of a transitional period to come.

Does This Vaccine-Maker's Upcoming Share Repurchase Make It a Buy?

BioCryst Pharmaceuticals

Exelixis

iTeos Therapeutics, Inc.

Moderna

Merus

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

7 Top-Rated Biotech Stocks to Buy for Q2

Intellia Therapeutics

Regeneron Pharmaceuticals

The hype has died down. Now it's time for science to take over.

3 Top Biotech Stocks Ready for a Bull Run

Beam Therapeutics

Arcus Biosciences

Vir Biotechnology

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

4 Undervalued Biotech Stocks to Add to Your Buy List

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

News for BioNTech SE Stock (BNTX)